RecruitingPhase 1NCT07226726
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
20 participants
Start Date
Jan 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
- Patients must be able to provide informed consent, or have a guardian who does.
- Patient must be able to travel to the site of treatment.
Exclusion Criteria1
- Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAlloEx exosomes
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07226726
Related Trials
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT064367429 locations
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT0607855320 locations